Clinical Trial

A Clinical Study Comparing the Bioavailability of HRS-2189 Tablets

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 10, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-center, single-dose, randomized, open-label, two-period, crossover phase I clinical trial, comparing the bioavailability and safety of the new and old processes of HRS-2189 tablets in healthy subjects.
Trial Details
NCT Number NCT07639905
Lead Sponsor Shandong Suncadia Medicine Co., Ltd.
Conditions Malignant Solid Tumor
Enrollment 28 participants
Start Date 2026-06
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-10